Literature DB >> 15527100

Neuro-oncology in a nutshell.

Joachim M Baehring1.   

Abstract

Mesh：

Year:  2004        PMID： 15527100

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  18 in total

Review 1.  Development of novel targeted therapies in the treatment of malignant glioma.

Authors:  Jeremy N Rich; Darell D Bigner
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

2.  Multiple meningiomas in brain and lung due to acquired mutation of the NF2 gene.

Authors:  O Eckstein; A Stemmer-Rachamimov; F Nunes; D Hoch; R Ojemann; M MacCollin
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

Review 3.  Targeted therapy for brain tumours.

Authors:  Maciej S Lesniak; Henry Brem
Journal:  Nat Rev Drug Discov       Date:  2004-06       Impact factor: 84.694

4.  First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.

Authors:  Alba A Brandes; Umberto Basso; Michele Reni; Francesca Vastola; Alicia Tosoni; Giovanna Cavallo; Luciano Scopece; Andres J Ferreri; Maria G Panucci; Silvio Monfardini; Mario Ermani
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

5.  Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.

Authors:  Shakeel Modak; Sharon Gardner; Ira J Dunkel; Casilda Balmaceda; Marc K Rosenblum; Douglas C Miller; Steven Halpern; Jonathan L Finlay
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

6.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

7.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

8.  Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.

Authors:  Christopher S Gondi; Sajani S Lakka; Niranjan Yanamandra; William C Olivero; Dzung H Dinh; Meena Gujrati; C H Tung; Ralph Weissleder; Jasti S Rao
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

9.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

10.  Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.

Authors:  Jing Yang; Sendurai A Mani; Joana Liu Donaher; Sridhar Ramaswamy; Raphael A Itzykson; Christophe Come; Pierre Savagner; Inna Gitelman; Andrea Richardson; Robert A Weinberg
Journal:  Cell       Date:  2004-06-25       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.